RUBIUS THERAPEUTICS INC's ticker is RUBY and the CUSIP is 78116T103. A total of 108 filers reported holding RUBIUS THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $961,600 | -43.1% | 174,519 | 0.0% | 0.00% | – |
| Q4 2021 | $1,689,000 | -45.9% | 174,519 | 0.0% | 0.00% | -100.0% |
| Q3 2021 | $3,120,000 | -26.8% | 174,519 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $4,260,000 | -57.7% | 174,519 | -54.1% | 0.00% | -50.0% |
| Q1 2021 | $10,070,000 | +194.8% | 380,000 | -15.6% | 0.00% | +100.0% |
| Q4 2020 | $3,416,000 | +51.5% | 450,000 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $2,255,000 | -16.2% | 450,000 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $2,691,000 | +34.3% | 450,000 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $2,003,000 | -53.1% | 450,000 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $4,275,000 | +21.0% | 450,000 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $3,533,000 | -50.1% | 450,000 | 0.0% | 0.00% | -50.0% |
| Q2 2019 | $7,079,000 | -13.1% | 450,000 | 0.0% | 0.00% | -33.3% |
| Q1 2019 | $8,145,000 | +12.6% | 450,000 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $7,236,000 | -33.0% | 450,000 | 0.0% | 0.00% | -25.0% |
| Q3 2018 | $10,800,000 | – | 450,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARCH Venture Management, LLC | 2,618,351 | $41,187,000 | 42.64% |
| Flagship Pioneering Inc. | 38,296,526 | $602,404,000 | 26.08% |
| HARBOURVEST PARTNERS LLC | 1,973,756 | $31,048,000 | 5.81% |
| Artal Group S.A. | 2,833,791 | $44,576,000 | 1.80% |
| EcoR1 Capital, LLC | 463,152 | $7,285,000 | 0.74% |
| Cormorant Asset Management, LP | 600,000 | $9,438,000 | 0.54% |
| Nikko Asset Management Americas, Inc. | 1,254,158 | $19,728,000 | 0.39% |
| Leap Investments LP | 14,100 | $222,000 | 0.30% |
| ARK Investment Management | 698,402 | $10,986,000 | 0.28% |
| Baillie Gifford | 4,234,682 | $66,612,000 | 0.07% |